Curr Oncol. 2021 Aug 25;28(5):3251-3258. doi: 10.3390/curroncol28050282. ABSTRACT PURPOSE: To describe the initial experience of an academic center using 18F-DCFPyL PET in managing men with recurrent prostate cancer. MATERIALS & METHODS: This prospective, single-arm IRB-approved study included men with biochemical…
Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada
Front Oncol. 2021 Aug 2;11:722430. doi: 10.3389/fonc.2021.722430. eCollection 2021. ABSTRACT Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming established as a standard of care for the (re)staging of high-risk primary and prostate cancer recurrence after primary…
Neuroendocrine Tumors: Imaging Perspective
PET Clin. 2021 Jul;16(3):353-364. doi: 10.1016/j.cpet.2021.03.002. ABSTRACT This article summarizes the role of PET imaging for detection, characterization, and theranostic/therapy planning for neuroendocrine tumors. Topics in this article span overall imaging accuracy with mostly 68Ga-DOTA-peptide imaging as well as basic…
Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3702-3711. doi: 10.1007/s00259-021-05355-7. Epub 2021 Apr 12. ABSTRACT PURPOSE: To assess whether 18F-DCFPyL PET/multiparametric (mp)MR contributes to the diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients with suspicion…
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6. ABSTRACT BACKGROUND: The hypothesis of a curable oligometastatic prostate cancer (PCa) state remains to be clinically-proven. Conventional imaging often fails to localize early recurrences, hampering the potential for radical approaches.…
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
J Nucl Med. 2021 Oct;62(10):1406-1414. doi: 10.2967/jnumed.120.256727. Epub 2021 Feb 12. ABSTRACT The aim of this study was to determine whether quantitative PET parameters on baseline 68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of therapy are…
Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging
Adv Radiat Oncol. 2020 Sep 9;6(1):100553. doi: 10.1016/j.adro.2020.08.010. eCollection 2021 Jan-Feb. ABSTRACT PURPOSE: Our purpose was to investigate the effect of the addition of prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) in patients with recurrent prostate cancer post-primary…
Case series – 18F-DCFPyL-positron emission tomography/computed tomography (PET/CT) time of imaging
Can Urol Assoc J. 2021 Jul;15(7):E376-E379. doi: 10.5489/cuaj.6984. NO ABSTRACT PMID:33382375 | PMC:PMC8279245 | DOI:10.5489/cuaj.6984
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
J Nucl Med. 2021 Oct;62(10):1406-1414. doi: 10.2967/jnumed.120.256727. Epub 2021 Feb 12. ABSTRACT The aim of this study was to determine whether quantitative PET parameters on baseline 68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of therapy are…
Nuclear medicine and molecular imaging advances in the 21st century
Br J Radiol. 2020 Jun;93(1110):20200095. doi: 10.1259/bjr.20200095. Epub 2020 May 13. ABSTRACT Currently, Nuclear Medicine has a clearly defined role in clinical practice due to its usefulness in many medical disciplines. It provides relevant diagnostic and therapeutic options leading to…